In gliomas, the variant III of the epidermal growth factor receptor (EGFRvIII), which results from an in-frame intragenic deletion of EGFR exons 2–7, is present in approximately 20% to 30% of glioblastomas and a recognized target in many peptide vaccination studies [21,22,23]. This evidence concerns the gene EGFR and central nervous system cancer.